Clinical Trials
3 trialsNCT05297890 2026-05-19
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals
Phase 2 Active not recruiting
NCT07415005 2026-05-05
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated